About Regeners
Regeners is a company based in Yuseong (South Korea) founded in 2021 by Ha-gang Kim. Regeners offers products and services including Stem Cell Therapeutics and Direct Reprogramming Technology. Regeners operates in a competitive market with competitors including UCB, Cellino, NuVasive, Ensoma and Aspen Neuroscience, among others.
- Headquarter Yuseong, South Korea
- Founders Ha-gang Kim
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website regenersinc.com
- Social LinkedIn
- Legal Name ㈜리제너스
- Date of Incorporation 10 Aug, 1977
- Jurisdiction Maharashtra, India
Associated legal entities of Regeners
Regeners operates through , (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| , CIN U99999MH1977PLC010754 | Active | 10 Aug 1977 | Nanded, Maharashtra | – | – | – | View details |
Products & Services of Regeners
Regeners offers a comprehensive portfolio of products and services, including Stem Cell Therapeutics and Direct Reprogramming Technology.
Develops treatments for Parkinson's using direct reprogramming technology.
Enables efficient cell conversion for disease therapies.
People of Regeners
1 people are tracked at Regeners (1 in leadership).
| Name | Role | Group |
|---|---|---|
Ha-gang Kim | Founder & CEO | Leadership |
Complete people profiles for Regeners
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Competitors of Regeners
Regeners operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as UCB, Cellino, NuVasive, Ensoma and Aspen Neuroscience, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ucb.com | 1928 | Brussels, Belgium | – | 79 | Therapies for immunological and neurological disorders are developed. | |
| cellinobio.com | 2017 | Cambridge, United States | $125M | 63 | Developer of autologous cell therapies | |
| nuvasive.com | 1997 | San Diego, United States | $54.1M | 2,450 | Smart surgical devices for spinal surgery are developed. | |
| ensoma.com | 2019 | Boston, United States | $205M | 52 | Provider of in vivo stem cell modification technologies and vector-based drug delivery tool | |
| aspenneuroscience.com | 2018 | San Diego, United States | $224M | – | Provider of genomic-based personalised pluripotent stem cell therapy | |
| avitamedical.com | 1992 | Cambridge, United Kingdom | – | 108 | Products for regenerative and respiratory medicine are developed and distributed. | |
| organogenesis.com | 1985 | Canton, United States | $30M | 856 | Regenerative therapies for wound care are developed and commercialized. | |
| treefrog.fr | 2018 | Talence, France | $84.25M | – | Developer of stem cells and organoids using proprietary technology | |
| pandorum.com | 2011 | Bengaluru, India | $36.82M | 28 | Regenerative medicine and 3D tissues are developed for therapeutic uses. |
Detailed competitors of Regeners
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Regeners
10 companies that operate in the same segment as Regeners (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 300 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 194 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Regeners
Regeners was founded in 2021.
Regeners is headquartered in Yuseong, South Korea. It is registered at Yuseong, Daejeon, South Korea.
Ha-gang Kim is the current CEO of Regeners. They have also founded this company.
Regeners was founded in 2021 and is based in Yuseong, South Korea. Operations focus on the biotechnology sector, where stem cell therapeutics are advanced through a direct cross-differentiation platform. Regenerative therapies offered include RG101, an autologous cell therapy for Parkinsons disease that involves creating and transplanting patient-specific dopaminergic neurons, and RG201 for macular degeneration. Development emphasizes patient-specific treatments in neurology and ophthalmology.
Regeners offers Stem Cell Therapeutics and Direct Reprogramming Technology.
Regeners operates through ,.